Cancer
Australian researchers at the Olivia Newton-John Cancer Research Institute (ONJCRI) and WEHI have made a significant discovery in the field of blood cancer research. By studying a single mutation in the DNA sequence for a methylation enzyme, they have identified a potential target for effective blood cancer treatment. This mutation,
Cancer
Tempus AI, Inc. and Boehringer Ingelheim have entered a new strategic collaboration to accelerate the discovery and development of new treatments for hard-to-treat cancers. This multi-year agreement builds on the companies' existing partnership, leveraging data and artificial intelligence to drive therapeutic research and development. The collaboration aims to explore
Cancer research
Research from Duke University emphasizes the urgent need for effective strategies to protect immunocompromised cancer patients during the COVID-19 pandemic, as disruptions in cancer care have led to worsened health outcomes. The pandemic has exacerbated vulnerabilities in cancer care, delaying diagnoses and treatment protocols. Long-term health consequences, including the emergence
Cancer research
Scientists have been studying mRNA since its discovery in 1961, but its application in vaccines has only recently gained widespread attention. Health Secretary Robert F. Kennedy Jr. has expressed concerns about the safety of mRNA vaccines, but mRNA is a naturally occurring molecule used to make every protein in our
Cancer research
Current research on cancer gene therapy has revealed promising results in the classification and prognosis of esophageal squamous cell carcinoma (ESCC). Researchers at Zhengzhou University have integrated single-cell RNA-sequencing and bulk RNA-seq analyses to characterize ESCC, identifying four distinct subtypes with unique cell type features and prognoses. A four-gene prognostic
Cancer research
Gastric cancer is a complex and challenging disease to detect, especially when diagnosed at a locally advanced stage. Current screening approaches, such as random biopsies during upper endoscopy, lack sensitivity and often result in five-year survival rates below 30%. In a significant breakthrough, Lumicell, Inc., a leader in developing innovative
Cancer research
Researchers from the Institute for Cancer Research and Treatment (IRCCS) in Ancona, Italy, have developed a machine learning framework using radiomics to predict hospitalization length in COVID-19 patients. The team extracted quantitative imaging features from CT scans and applied a machine learning algorithm to accurately predict hospitalization duration. The study
Cancer research
As the patent landscape shifts in the global oncology market, Hyundai ADM Bio (KOSDAQ symbol 187660) is rebalancing its focus towards immunotherapy-based combinations, abandoning its IND application for Phase 1 clinical trials involving Penetrium(TM) and docetaxel. This strategic redirection reflects a broader shift in the industry, driven by the
Cancer
In a landmark study, researchers at the Institute for Cancer Research and Treatment (IRCCS) San Raffaele Scientific Institute have found that intravenous amino acid therapy significantly decreases the occurrence of acute kidney injury in cardiac surgery patients, particularly those with chronic kidney disease. This breakthrough research, published in the journal
Cancer
Research published in Internal Medicine journal revealed a case of an 11-year-old boy who developed cardioembolic stroke (CES) and cancer therapy-related cardiac dysfunction (CTRCD) despite effective treatment with high-dose chemotherapy. The patient was admitted with severe aphasia and magnetic resonance imaging showed occlusion of the left middle cerebral artery M3
Cancer
Researchers at the University of Helsinki have made significant progress in cancer gene therapy by developing a novel method for delivering mRNA to lung endothelium and immune cells, including T cells, with low in vivo toxicity. This breakthrough marks a crucial step towards effective treatment of various cancers, including lung
Cancer genetics
The Bombay high court has issued a notice to the Central Drugs Standard Control Organisation (CDSCO) to respond to a petition filed by Datar Cancer Genetics Pvt Ltd, a Nashik-based cancer research company seeking permission to conduct phase one human trials of its cancer immunotherapy drug, Per-C-Vax. The company claims
